Frontlight ResearchEarly access
Taking people in NetherlandsPhase 1
E-VIM Vaccine CVX1 With or Without Immunotherapy for Bladder or Kidney Cancer
Tests the E-VIM vaccine CVX1 in adults with bladder or kidney cancer.
Key facts
- Who runs it
- CimCure B.V.
- Where
- Amsterdam, Leiden, and Rotterdam, NetherlandsSee the 4 sites
- Trial code
- Registry title
- PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC) OR LOCALIZED OR LOCALLY ADVANCED RENAL CELL CANCER (RCC).
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 83 people, planned
- Started
- 2 Apr 2026
- Expected to end
- 31 Mar 2029
- Type of study
- Interventional
- Record updated
- 14 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with muscle invasive bladder cancer or localized or locally advanced kidney cancer (renal cell cancer). It tests the safety of the E-VIM vaccine CVX1, with or without an immune checkpoint inhibitor (ICI).
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Muscle invasive bladder cancer, or localized or locally advanced renal cell cancer (RCC)
Where in Netherlands
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
- Netherlands Cancer InstituteAmsterdam, NetherlandsTaking people
- Leids Universitair Medisch Centrum (LUMC)Leiden, NetherlandsTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- E-VIM Vaccine CVX1 With or Without Immunotherapy for Bladder or Kidney CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 14 September 2026